In an adult with suspected internal bleeding, how and when should tranexamic acid (TXA) be administered, including dosing regimen, contraindications, and renal function adjustments?

TXA for Suspected Internal Bleeding

Administer tranexamic acid 1 g IV over 10 minutes as soon as possible—ideally within the first hour and no later than 3 hours after injury—followed by 1 g IV infusion over 8 hours in any adult with suspected internal bleeding from trauma. 1, 2

Timing is Critical for Mortality Benefit

The window for TXA administration directly determines survival outcomes:

• Within 1 hour of injury: Maximum mortality reduction with relative risk of death from bleeding of 0.68 (32% reduction) 1
• Between 1-3 hours: Moderate benefit persists with RR 0.79 (21% reduction) 1
• After 3 hours: Treatment effect disappears and may actually increase risk of death from hemorrhage (RR 1.44), though not all-cause mortality 1, 2, 1

The 3-hour cutoff is an absolute contraindication—do not administer TXA beyond this timeframe. 1

Standard Dosing Regimen

The evidence-based protocol from the CRASH-2 trial (20,211 patients) remains the gold standard 1, 2:

• Loading dose: 1 g IV over 10 minutes
• Maintenance: 1 g IV infusion over 8 hours
• Total dose: 2 g over approximately 8 hours

This regimen reduced all-cause mortality from 16.0% to 14.5% (RR 0.91) and death from bleeding from 5.7% to 4.9% (RR 0.85) 1

Alternative Dosing Considerations

While the standard 2 g regimen is recommended, emerging evidence suggests potential modifications 2:

• Single 1 g bolus: May be equivalent to bolus-plus-infusion for clinical outcomes and is logistically simpler 3
• Higher doses (up to 3 g): The STAAMP trial suggests repeated dosing up to 3 g total in hypotensive patients, though this remains investigational 2

For practical implementation, the single 1 g bolus is likely preferable to bolus-plus-infusion given equivalent outcomes and simplified administration. 3

Patient Selection Criteria

TXA should be administered to trauma patients with 1, 2:

• Active bleeding OR risk of significant hemorrhage defined as:
  • Systolic blood pressure <90 mmHg, OR
  • Heart rate >110 bpm, OR
  • Clinical judgment of significant bleeding risk

Do not restrict TXA to only the most severely injured—mortality reduction is consistent regardless of baseline probability of death. 2

Contraindications

Absolute contraindications 4:

• Subarachnoid hemorrhage (risk of cerebral edema and infarction)
• Active intravascular clotting
• Severe hypersensitivity to TXA

Relative caution (not absolute contraindications in trauma):

• History of seizures (increased risk with high doses >2 g) 1
• Gastrointestinal bleeding specifically (increased VTE risk in this population) 5

Renal Function Adjustments

The FDA label provides specific guidance for renal impairment 4:

Standard trauma dosing does not require adjustment for most patients, as the 2 g total dose over 8 hours is well below thresholds requiring modification. However, for context:

• Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg IV twice daily
• Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg IV once daily
• Serum creatinine >5.66 mg/dL: 5 mg/kg IV once daily

In chronic kidney disease patients, TXA accumulates and clearance is reduced 6. For trauma patients with known severe renal impairment (eGFR <30), consider reducing the maintenance infusion dose by 50% or using single bolus only. 6

Administration Route and Technique

• Intravenous route only—never administer via neuraxial route (risk of seizures) 4
• Infusion rate: No faster than 1 mL/minute to avoid hypotension 4
• Pre-hospital administration: Strongly consider giving the first 1 g bolus en route to hospital 1

Safety Profile in Trauma

TXA does not increase thrombotic risk in trauma patients 1:

• CRASH-2 showed lower rates of myocardial infarction with TXA
• No increase in venous thromboembolism in trauma populations 2
• The PATCH trial confirmed no difference in thrombotic events (23.6% vs 19.7%) 2

Important caveat: This safety profile is specific to trauma. In gastrointestinal bleeding, TXA increases VTE risk (RR 2.01 for DVT, 1.78 for PE) and should not be used 5

Common Pitfalls to Avoid

1. Waiting for laboratory confirmation: Do not delay TXA for viscoelastic testing or coagulation studies—administer based on clinical criteria alone 7

2. Delaying for "massive transfusion protocol": TXA benefits all bleeding trauma patients, not just those with massive hemorrhage 1

3. Administering after 3 hours: This is harmful—the mortality benefit reverses 1

4. Using in non-traumatic internal bleeding: Evidence is specific to trauma; do not extrapolate to spontaneous bleeding without trauma mechanism 8

5. Excessive dosing: Doses >2 g increase seizure risk without additional benefit 1